Who
Theresa Heggie
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals.
In numbers
- Trades disclosed
- 49
- Buys
- 1
- Sells
- 3
- Bought
- $7,250
- Sold
- $1.6M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 3 Dec 2018
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $315K49,933 at $6.30 | filing |
| 20 Mar 2026filed 24 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $505K49,933 at $10.11 | filing |
| 20 Mar 2026filed 24 Mar 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,933 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,933 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $315K49,933 at $6.30 | filing |
| 20 Mar 2026filed 24 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $505K49,933 at $10.11 | filing |
| 13 Aug 2025filed 15 Aug 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 13 Aug 2025filed 15 Aug 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 13 Aug 2025filed 15 Aug 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $87K30,000 at $2.91 | filing |
| 13 Aug 2025filed 15 Aug 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $216K40,000 at $5.41 | filing |
| 13 Aug 2025filed 15 Aug 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $596K70,000 at $8.51 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,181 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 14 Jun 2024filed 14 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K6,698 at $6.11 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,933 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,820 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.